Search Results

Kura Oncology, Inc. today announced its participation in Stifel 2024 Targeted Oncology Forum.

Ziopharm Oncology, Inc. today highlighted recent operational and corporate updates.

Pyxis Oncology, Inc., a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology’s common stock to five newly hired employees.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, provided updates on its oncology pipeline at an investor meeting.

Kura Oncology, Inc. today reported preclinical data supporting the potential therapeutic utility of menin inhibitors in the treatment of diabetes.